{"date": "2022-02-04 18:44:54+00:00", "ticker": "ABDN", "mrkt_info": {"open": 243.3, "close": 243.0}, "html": "<div class=\"storyContent\" lang=\"en\"><style type=\"text/css\">.storyContent * {border-color:inherit !important;outline-color:inherit !important;}</style><p class=\"tr-story-p1\">** Shares of diagnostic company <a href=\"reuters://REALTIME/Verb=FullQuote/ric=SLGC.O\" data-type=\"ric\" data-ric=\"SLGC.O\" translate=\"no\" dir=\"ltr\">SLGC.O</a> rise 3.8% to $8.74 </p><p>** SLGC says it expects 2022 revenue in range of about $105 mln to $110 mln, above Refinitiv IBES estimates of $103.5 mln <span> (<a href=\"reuters://REALTIME/verb=NewsStory/ric=nGNX6lF37r\" data-type=\"storyId\" data-story-id=\"nGNX6lF37r\" translate=\"no\" dir=\"ltr\" class=\"tr-pnac\">Full Story</a>)</span></p><p>** SLGC, which has 'proteomics' platform designed to measure blood proteins and potentially help identify disease markers, had announced partnership with Illumina <a href=\"reuters://REALTIME/Verb=FullQuote/ric=ILMN.O\" data-type=\"ric\" data-ric=\"ILMN.O\" translate=\"no\" dir=\"ltr\">ILMN.O</a> in Jan</p><p>** SLGC's efforts in diversifying its offerings coupled with increasing demand for proteomics services implies an \"incredibly bright\" future for company - CEO</p><p>** Including session moves, SLGC fell 14.7% since it went public in September through business combination with blank- check firm CM Life Sciences II Inc</p><p><br/></p><p class=\"tr-signoff\"> (Reporting by Amruta Khandekar)</p><p class=\"tr-contactinfo\">(( <a href=\"mailto:Amruta.Khandekar@thomsonreuters.com\" data-type=\"email\" translate=\"no\">Amruta.Khandekar@thomsonreuters.com</a> ;))</p><p class=\"line-break\"><br/></p><p class=\"tr-copyright\">(c) Copyright Thomson Reuters 2022. Click For Restrictions - https://agency.reuters.com/en/copyright.html</p></div>"}